A study by researchers at the Queen Mary University of London has found that a drug blocked by European regulators can improve the quality of life for people with multiple sclerosis.
The team of researchers reached this conclusion after uncovering previously unpublished clinical trial data from the European Medicines Agency. The European Commission is currently considering whether it will reverse its decision to deny a license for the oral formulation of the drug, cladribine.
Get the full story at our sister site, Drug Delivery Business News.
The post Drug blocked by European regulators improves quality of life for MS patients appeared first on MassDevice.